Immunotherapeutic concepts to target acute myeloid leukemia

Focusing on the role of monoclonal antibodies, hypomethylating agents and the leukemic microenvironment

Olumide Babajide Gbolahan, Amer M. Zeidan, Maximilian Stahl, Mohammad Abu Zaid, Sherif Farag, Sophie Paczesny, Heiko Konig

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

Intensive chemotherapeutic protocols and allogeneic stem cell transplantation continue to represent the mainstay of acute myeloid leukemia (AML) treatment. Although this approach leads to remissions in the majority of patients, long-term disease control remains unsatisfactory as mirrored by overall survival rates of approximately 30%. The reason for this poor outcome is, in part, due to various toxicities associated with traditional AML therapy and the limited ability of most patients to tolerate such treatment. More effective and less toxic therapies therefore represent an unmet need in the management of AML, a disease for which therapeutic progress has been traditionally slow when compared to other cancers. Several studies have shown that leukemic blasts elicit immune responses that could be exploited for the development of novel treatment concepts. To this end, early phase studies of immune-based therapies in AML have delivered encouraging results and demonstrated safety and feasibility. In this review, we discuss opportunities for immunotherapeutic interventions to enhance the potential to achieve a cure in AML, thereby focusing on the role of monoclonal antibodies, hypomethylating agents and the leukemic microenvironment.

Original languageEnglish (US)
Article number1660
JournalInternational Journal of Molecular Sciences
Volume18
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Disease control
Monoclonal antibodies
leukemias
Poisons
Stem cells
antibodies
Acute Myeloid Leukemia
Toxicity
Monoclonal Antibodies
therapy
Therapeutics
transplantation
stem cells
blasts
toxicity
safety
Stem Cell Transplantation
cancer
Survival Rate
Safety

Keywords

  • Acute myeloid leukemia
  • Hypomethylating agents
  • Immunotherapy
  • Microenvironment
  • Monoclonal antibodies

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Computer Science Applications
  • Spectroscopy
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

Immunotherapeutic concepts to target acute myeloid leukemia : Focusing on the role of monoclonal antibodies, hypomethylating agents and the leukemic microenvironment. / Gbolahan, Olumide Babajide; Zeidan, Amer M.; Stahl, Maximilian; Zaid, Mohammad Abu; Farag, Sherif; Paczesny, Sophie; Konig, Heiko.

In: International Journal of Molecular Sciences, Vol. 18, No. 8, 1660, 01.08.2017.

Research output: Contribution to journalReview article

@article{262dc08254324c9e9488b53ed08f324e,
title = "Immunotherapeutic concepts to target acute myeloid leukemia: Focusing on the role of monoclonal antibodies, hypomethylating agents and the leukemic microenvironment",
abstract = "Intensive chemotherapeutic protocols and allogeneic stem cell transplantation continue to represent the mainstay of acute myeloid leukemia (AML) treatment. Although this approach leads to remissions in the majority of patients, long-term disease control remains unsatisfactory as mirrored by overall survival rates of approximately 30{\%}. The reason for this poor outcome is, in part, due to various toxicities associated with traditional AML therapy and the limited ability of most patients to tolerate such treatment. More effective and less toxic therapies therefore represent an unmet need in the management of AML, a disease for which therapeutic progress has been traditionally slow when compared to other cancers. Several studies have shown that leukemic blasts elicit immune responses that could be exploited for the development of novel treatment concepts. To this end, early phase studies of immune-based therapies in AML have delivered encouraging results and demonstrated safety and feasibility. In this review, we discuss opportunities for immunotherapeutic interventions to enhance the potential to achieve a cure in AML, thereby focusing on the role of monoclonal antibodies, hypomethylating agents and the leukemic microenvironment.",
keywords = "Acute myeloid leukemia, Hypomethylating agents, Immunotherapy, Microenvironment, Monoclonal antibodies",
author = "Gbolahan, {Olumide Babajide} and Zeidan, {Amer M.} and Maximilian Stahl and Zaid, {Mohammad Abu} and Sherif Farag and Sophie Paczesny and Heiko Konig",
year = "2017",
month = "8",
day = "1",
doi = "10.3390/ijms18081660",
language = "English (US)",
volume = "18",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "8",

}

TY - JOUR

T1 - Immunotherapeutic concepts to target acute myeloid leukemia

T2 - Focusing on the role of monoclonal antibodies, hypomethylating agents and the leukemic microenvironment

AU - Gbolahan, Olumide Babajide

AU - Zeidan, Amer M.

AU - Stahl, Maximilian

AU - Zaid, Mohammad Abu

AU - Farag, Sherif

AU - Paczesny, Sophie

AU - Konig, Heiko

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Intensive chemotherapeutic protocols and allogeneic stem cell transplantation continue to represent the mainstay of acute myeloid leukemia (AML) treatment. Although this approach leads to remissions in the majority of patients, long-term disease control remains unsatisfactory as mirrored by overall survival rates of approximately 30%. The reason for this poor outcome is, in part, due to various toxicities associated with traditional AML therapy and the limited ability of most patients to tolerate such treatment. More effective and less toxic therapies therefore represent an unmet need in the management of AML, a disease for which therapeutic progress has been traditionally slow when compared to other cancers. Several studies have shown that leukemic blasts elicit immune responses that could be exploited for the development of novel treatment concepts. To this end, early phase studies of immune-based therapies in AML have delivered encouraging results and demonstrated safety and feasibility. In this review, we discuss opportunities for immunotherapeutic interventions to enhance the potential to achieve a cure in AML, thereby focusing on the role of monoclonal antibodies, hypomethylating agents and the leukemic microenvironment.

AB - Intensive chemotherapeutic protocols and allogeneic stem cell transplantation continue to represent the mainstay of acute myeloid leukemia (AML) treatment. Although this approach leads to remissions in the majority of patients, long-term disease control remains unsatisfactory as mirrored by overall survival rates of approximately 30%. The reason for this poor outcome is, in part, due to various toxicities associated with traditional AML therapy and the limited ability of most patients to tolerate such treatment. More effective and less toxic therapies therefore represent an unmet need in the management of AML, a disease for which therapeutic progress has been traditionally slow when compared to other cancers. Several studies have shown that leukemic blasts elicit immune responses that could be exploited for the development of novel treatment concepts. To this end, early phase studies of immune-based therapies in AML have delivered encouraging results and demonstrated safety and feasibility. In this review, we discuss opportunities for immunotherapeutic interventions to enhance the potential to achieve a cure in AML, thereby focusing on the role of monoclonal antibodies, hypomethylating agents and the leukemic microenvironment.

KW - Acute myeloid leukemia

KW - Hypomethylating agents

KW - Immunotherapy

KW - Microenvironment

KW - Monoclonal antibodies

UR - http://www.scopus.com/inward/record.url?scp=85026732468&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026732468&partnerID=8YFLogxK

U2 - 10.3390/ijms18081660

DO - 10.3390/ijms18081660

M3 - Review article

VL - 18

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 8

M1 - 1660

ER -